Study	Reason for exclusion
Acévedo 2004	Oocyte donation programme, donors and recipients.
Barberi 2012	A quasi‐randomised controlled trial.
Baruffi 2006	Study design (literature review) not relevant.
Cedrin‐Durnerin 2004	Pseudo‐randomised trial, according to women's birthdays.
Cedrin‐Durnerin 2008	rLH was administered before OS with rFSH (as pre‐treatment).
De Placido 2004	Comparison of two different rLH doses.
De Placido 2006	Comparison of GnRH antagonist versus GnRH agonist.
Drakakis 2005	Comparison of hMG versus rFSH.
Fei Yang 2013	Compared rLH/hCG/rFSH versus HP‐hMG/rFSH/HCG versus HP‐HMG/rFSH.
Fermin 2013	Compared rFSH/rLH versus rFSH/rLH using 2 different doses.
Garcia‐Velasco 2007	Interventions not relevant; GnRH agonist versus cetrorelix (GnRH antagonist).
Gomez‐Palomares 2005	comparison of hMG versus rFSH and rLH.
Hugues 2005	Inclusion of WHO group II anovulatory women.
Lahoud 2010	Study design not relevant.
Lisi 2003	Not a randomised trial.
Motta 2006	Use of GnRH agonist versus antagonist protocols for downregulation.
Papanikolaou 2010	rLH is used as luteal support.
Sauer 2004	Interventions not relevant: GnRH agonist (leuprolide) + rFSH versus GnRH antagonist (cetrorelix) with or without rLH.
Sills 1999	Comparison of HP‐FSH versus rFSH.
Tesarik 2002	Comparison of hMG versus rFSH.
Topercerová 2005	Interventions not relevant.

Abbreviations:

AFC: antral follicle count

AMH: anti‐Mullerian hormone

b‐hCG: beta hCG

OS: ovarian stimulation

E2: estradiol

FSH: follicle ‐stimulating hormone

GnRH: gonadotrophin‐releasing hormone

HBV: hepatitis B

HCV: hepatitis C

hCG: human chorionic gonadotrophins

hMG: human menopausal gonadotrophin

HP‐hMG: highly purified hMG

HMG: human menopausal gonadotrophins

mIU: milli‐international units

OC: oral contraceptive

PN: pronucleus

PCOS: polycystic ovary syndrome

rhCG: recombinant hCG

rLH: recombinant luteinizing hormone

rFSH: recombinant luteinizing hormone

IU: international units

VEGF: vascular endothelial growth factor

WHO: World Health Organization